4:32 PM ET
8-K
Clinical Trial Data
Citius Oncology Clinical Trial Data
Citius Oncology announced positive health-related quality of life (HRQoL) results from its pivotal Study 302 of LYMPHIR in patients with relapsed or refractory cutaneous T-cell lymphoma. Data presented at the EORTC-CLTG 2026 Annual Meeting showed that patients who responded to treatment reported sustained improvements in skin-related quality of life and significant reductions in pruritus (itching).